Quantcast

Latest metronidazole Stories

2009-03-25 05:30:00

- Up to $50 Million Potential Milestones plus Double Digit Royalties on Future Sales - - Company to Host Conference Call at 11:00 a.m. ET Today - EMERYVILLE, Calif., March 25 /PRNewswire-FirstCall/ -- NovaBay Pharmaceuticals, Inc. (NYSE Amex: NBY), a mid-stage biopharmaceutical company developing first-in-class anti-infective products for the treatment and prevention of a wide range of infections without causing resistance, today announced that it has entered into an agreement with...

2009-03-03 14:17:17

Resent studies reported that aspirin inhibited the growth of H. pylori in a dose-dependent manner and significantly affected the activity of virulence factors of H. pylori. In addition, aspirin increased the susceptibility of H. pylori to antimicrobials including metronidazole, clarithromycin and amoxicillin. However, the mechanisms remained unknown. A research team led by Prof. Wang from Peking University First Hospital of China addressed this issue and their results will be published on...

2009-02-03 08:30:00

FORT WORTH, Texas, Feb. 3 /PRNewswire/ -- Galderma Laboratories, L.P. today announced that the U.S. Food and Drug Administration (FDA) has approved Vectical(TM) (calcitriol) Ointment 3mcg/g, a unique vitamin D3 product for the treatment of mild-to-moderate plaque psoriasis in adults. Psoriasis is a chronic skin disorder that affects 2 to 3 percent of the U.S. population. It is characterized by thick, red, scaly patches of skin and caused by an abnormally high growth rate of skin...

2009-02-03 07:00:00

SAN ANTONIO, Feb. 3 /PRNewswire/ -- BioComp Pharma, Inc. launched Tinidazole 500, the first generic version of the FDA-approved drug Tindamax(R). Tindamax(R) is the only oral antimicrobial drug approved by the FDA for the treatment of both trichomoniasis (trich) and bacterial vaginosis (BV). BioComp Pharma will begin shipping the generic version of Tindamax(R) in February 2009. Generic drugs have the same active ingredients and efficacy as branded drugs but, on average, cost 30 to 80...

2009-01-06 08:30:00

Epiduo(TM) Gel Combines Retinoid and Benzoyl Peroxide in a Single Product; Performs Better than Either Component Alone FORT WORTH, Texas, Jan. 6 /PRNewswire/ -- Galderma Laboratories, L.P. today announced the availability of Epiduo(TM) (adapalene and benzoyl peroxide) Gel 0.1% / 2.5%, the first and only, once-daily, topical acne treatment that combines the well-tolerated retinoid adapalene, and benzoyl peroxide, a well-known antimicrobial with no evidence of promoting bacterial resistance....

2008-11-12 12:00:00

According to Optimer Pharmaceuticals, its lead anti-infective drug candidate, OPT-80, showed higher clinical cure, global cure and recurrence rates in Phase III trials for the treatment of Clostridium difficile than the current standard of care, Vancocin. As a result, Datamonitor believes that OPT-80 has the potential to satisfy the large unmet need for an improved C. difficile treatment. Optimer Pharmaceuticals has released positive top-line results from a pivotal Phase III clinical study...

2008-11-10 18:00:22

Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) today released positive top-line results from a pivotal Phase 3 clinical study of the Company's lead anti-infective drug candidate, OPT-80, in patients with Clostridium difficile Infection (CDI). 92.1% of patients treated with OPT-80 (per protocol population) achieved clinical cure vs. 89.8% for Vancocin. In addition, only 13.3% of patients treated with OPT-80 experienced a recurrence vs. 24.0% for Vancocin (p = 0.004). Patients treated with...

2008-08-26 03:00:17

By Chaudhry, Rama Joshy, Lovely; Kumar, Lalit; Dhawan, Benu Background & objectives: Frequent use of broad spectrum antibiotics in hospitalized patients has increased the incidence of Clostridium difficile diarrhoea in recent years. In our tertiary care hospital in north India, C. difficile was responsible for 15 per cent of cases of nosocomial diarrhoea in 1999. A retrospective study was carried out to determine the frequency of C. difficile associated diarrhoea (CdAD) in our hospital,...

2008-07-16 21:00:28

LAUSANNE, Switzerland, July 16 /PRNewswire/ -- Galderma Pharma S.A., a global specialty pharmaceutical company focused on dermatology, announced today that Japan's Ministry of Health, Labor and Welfare has approved Differin(R) Gel 0.1% (adapalene), a novel topical treatment for acne vulgaris in Japan. The drug will be marketed in Japan by Galderma KK, the fully-owned Japanese arm of Galderma, and strategic alliance partner Shionogi. Differin(R) has been available for over 15 years and is...

2008-06-26 18:01:55

Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) presented new data from its Phase 2A clinical study of OPT-80 finding a 42% presence of the super toxin-producing strain of C. difficile known as BI/NAP1/027 strain and concluded that there was no significant difference in the overall cure rates with OPT-80 between subjects with the BI/NAP1/027 strain and subjects without the hypervirulent strain. Data was presented today at the 9th Biennial Congress of the Anaerobe Society of the Americas...


Word of the Day
snash
  • To talk saucily.
  • Insolent, opprobrious language; impertinent abuse.
This word is Scots in origin and probably imitative.